Health
Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
Pre-randomization Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) set-up data from the MODERATO II randomized, prospective, multi-center, double-blind, controlled trial show an immediate average reduction of 13.2 mmHg in office systolic blood pressure (“oSBP”)97% of patients experienced an immediate blood pressure reduction of >5 mmHg reduction in oSBP prior to randomizationAVIM Therapy demonstrated the potential to deliver immediate, substantial, and sustained reductions in blood
About this update from Orchestra Biomed Holdings, Inc.
[{"type":"image","alt":"Orchestra BioMed Holdings, Inc.","displaySize":"","headline":null,"caption":"Orchestra BioMed Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":97,"url":"https://media.zenfs.com/en/globenewswire.com/82bb98ef85c6f29f82627c7205a5e888"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NF0Vi4jXeU.qEwCJsJR0AA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNg--/https://media.zenfs.com/en/globenewswire.com/82bb98ef85c6f29f82627c7205a5e888","width":300,"height":97}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Pre-randomization Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) set-up data from the MODERATO II randomized, prospective, multi-center, double-blind, controlled trial show an immediate average reduction of 13.2 mmHg in office systolic blood pressure (“oSBP”)","length":279,"tagName":"p"}]},{"val":[{"type":"text","content":"97% of patients experienced an immediate blood pressure reduction of >5 mmHg reduction in oSBP prior to randomization","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"AVIM Therapy demonstrated the potential to deliver immediate, substantial, and sustained reductions in blood pressure, with evidence of improved diastolic function and reverse cardiac remodeling","length":194,"tagName":"p"}]},{"val":[{"type":"text","content":"The BACKBEAT Global Pivotal Trial, which Orchestra BioMed is actively enrolling as part of a strategic collaboration with Medtronic (NYSE: MDT), targets a similar patient population as MODERATO II using a similar approach to blood pressure assessment and AVIM Therapy activation ","length":278,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":871,"olType":false},{"type":"text","content":"NEW HOPE, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced two AVIM Therapy presentations at the Heart Rhythm Society (HRS) 2026 Annual Meeting.","length":392,"tagName":"p"},{"type":"text","content":"HRS 2026 Presentations and Data HighlightsAtrioventricular Interval Modulation (AVIM) Therapy as a Treatment for Hypertensive Heart Disease (Saturday, Ap...